Home Latest Articles
Latest Articles
  • Lijia YUAN, Liqing WANG, Xiaoyan WANG, Ning ZHANG
    Chinese Journal of Pharmaceuticals. 2022, 53(11): 1529-1538.

    Difficulty in research and development(R&D) of pediatric drugs is a global problem. The high difficulty of R&D, high costs and long cycle of pediatric drugs, as well as the low market returns compared with the adult medicines because of the short medication cycle, aggravate the inactive R&D situation of pediatric drugs. In order to encourage the R&D of pediatric drugs in China, various countries have adopted many measures to acclerate the R&D of pediatric drugs. This paper summarizes and analyzes the special policies and related technical guidelines issued by US, EU, Japan and China to accelerate the review and approval of pediatric drugs, which will serve as a referance for Chinese pediatric drugs developers and the follow-up government regulation and policy makers.

  • Ying GENG, Hao ZHANG, Yonglin JIANG, Yanzhe SUN, Qiang LI, Zhimin YANG
    Chinese Journal of Pharmaceuticals. 2022, 53(11): 1539-1545.

    The goal of pediatric drug development is to provide safe, effective, quality controllable and suitable for children of different ages. It is common to expand pediatric drug applications to optimize improved new drugs with obvious clinical advantages based on drugs with known active ingredients. Based on investigational new drug(IND) application information accepted by the Center for Drug Evaluation from March 4, 2016 to June 30, 2022, this paper introduced the application and review of 2.2 category improved new chemical drugs for pediatric. Meanwhile, the application items approved and failed were sorted out, and the concerns of assessment to the purpose of the project were discussed to provide a reference for the application of 2.2 category improved new drugs.

  • Liqing WANG, Lijia YUAN, Ning ZHANG
    Chinese Journal of Pharmaceuticals. 2022, 53(11): 1546-1550.

    Since the reform of drug evaluation and approval system in 2015, China has established various policies for imported drugs and pediatric drugs. Imported drugs are of great value in satisfying pediatric clinical needs in China. This study aimed to understand the registration situation of imported drugs for children and provide policy suggestions through analysis on imported drugs approved for children since 2019.

  • Huanhuan CUI, Wendong LIU, Xiaohan WANG, Haixue WANG, Xian SU
    Chinese Journal of Pharmaceuticals. 2022, 53(11): 1551-1557.

    Refer to the EU Guidelines for pharmacovigilance of pediatric medicines, this paper analyzed the characteristics of adverse reactions in pediatric clinical trials and pediatric populations, and the main points of pharmacovigilance in pediatric populations. The pediatric population is in the stage of growth and development. The frequency and nature of adverse reactions are different from that of adults. According to the physiological and pathological characteristics of the pediatric population, they should be distinguished in terms of adverse reaction reporting and treatment, risk control, signal management, regular safety reports, and post-marketing research. Taking into account the current situation of pharmacovigilance construction during clinical trials in China, accelerate the establishment of a pharmacovigilance system for pediatric clinical trials and strengthen the protection of subjects in pediatric populations.

  • Jing CUI, Ning ZHANG
    Chinese Journal of Pharmaceuticals. 2022, 53(11): 1558-1564.

    The FDA and EMA regulatory policies for pediatric drugs are introduced from the aspects of regulatory policy establishment, implementation scope of pediatric study plan, review time limit and application requirements, some suggestions are put forward to further improve pediatric drug regulation in China. In combination with the revision of “Regulations for the Implementation of the Drug Administration Law” and the current situation of drug review resources, some recommendations are listed as follows: further improving the legal and regulatory system for the supervision of pediatric drugs, formulating relevant working procedures for pediatric study plan in line with the actual drug review condition in China, further supplementing the technical guidelines for pediatric drugs, guiding and standardizing research and development process for pediatric drugs of manufacturing enterprises, promoting pediatric drug innovative process, and effectively solving the unmet clinical needs of pediatric population in China.

  • Xiaolei SHAN, Fanghua HUANG, Kaidi JIANG
    Chinese Journal of Pharmaceuticals. 2022, 53(11): 1565-1570.

    In recent years, paediatric pharmaceutical has become a hotspot of drug development and clinical trials in paediatric population have gradually increased. The conduct of juvenile animal studies(JAS) should be considered only when previous nonclinical and clinical data are insufficient to support paediatric clinical trials. A JAS is designed to address safety concerns that cannot be adequately addressed in other nonclinical studies or paediatric clinical trials, including potential long-term safety effects. The ICH S11 Nonclinical safety testing in support of development of pediatric pharmaceuticals was issued in 2020. This article discusses considerations of JAS, combining with ICH S11 guidance and cases analysis, aiming to provide information for pediatric pharmaceutical development in China.

  • Lingling WANG, Zhen TANG, Jiping LI, Changming YANG
    Chinese Journal of Pharmaceuticals. 2022, 53(11): 1571-1578.

    Based on the analysis of the 2020 edition of Chinese Pharmacopoeia(Part I), the National Essential Drug Catalogue(2018 edition), and the investigational new drug applications of new traditional Chinese medicines(TCMs) for children in recent years, it is concluded that the pharmaceutical preparations of TCMs for children have the some problems, such as lack of pediatric drug fomulations, insufficient dosage forms, narrow range of therapeutic areas, and lack of safety data of excipients for children. According to the basic requirements in drug product technical review, the paper discusses the general considerations for the research and development of TCMs for children, from the following aspects: the basic requirements of pharmaceutical research of pharmaceutical preparations of TCMs, the characteristics of children's medication, the route of administration and dosage form design, the dosage accuracy, the suitability of packaging systems, the types and dosages of excipients, and quality control. It is hoped to provide some useful references for the development and research of pharmaceutical preparations of TCMs for children.

  • Yifan WU, Fuli LIU, Yamin WANG
    Chinese Journal of Pharmaceuticals. 2022, 53(11): 1579-1582.

    Based on the characteristics of oral solution for pediatric use, this paper summarizes and analyzes the relevant industry guidelines and guiding principles. In order to improve the quality of oral solution for pediatric use, the pharmaceutical concerns in research, development and evaluation are expounded.

  • Junwei MA, Lianjie REN
    Chinese Journal of Pharmaceuticals. 2022, 53(11): 1583-1587.

    The labelings of medicines lack information and have problems of incomplete and inaccurate descriptions on posology and method of administration for pediatrics. There is an urgent need to issue relevant requirements to provide standardized guidance for posology and method of administration for pediatrics. This paper introduces the main problems of posology and method of administration in the labelings of pediatric medicines, discusses the writing requirement from general consideration, medicine pretreatment, preparation method, and medicine usage instruction, and proposes recommendations for relevant pharmaceutical research. Considerations and suggestions were put forward on the research, development, and supervision of pediatric medicine in China.

  • Hongliang WANG, Zhenyu XU
    Chinese Journal of Pharmaceuticals. 2022, 53(11): 1588-1592.

    Childhood is a critical period for body growth and development. Adequate calcium intake is the basic guarantee for normal growth and healthy development of bones. Thereof, the development and quality control of calcium supplements for children are very important. Taking calcium gluconate tablets, calcium and zinc gluconate oral solution, chewable calcium carbonate tablets, calcium carbonate-vitamin D3 chewable tablets as the examples, aiming to provide the corresponding references for the industry, this paper simply analyzes the relevant considerations on pharmaceutical research of calcium supplements for children from the aspects of raw materials, excipients, packing materials, formulation and process, and quality research.

News